União Química seeks approval from Brazil’s CADE for acquisition of Bayer’s hormonal therapy drugs
Pharmaceutical company União Química Farmacêutica Nacional has submitted a full-form notification to the Brazilian competition authority for its proposed acquisition of manufacturing, commercialization, and intellectual property rights for the hormonal therapy...To view the full article, register now.
Already a subscriber? Click here to view full article